Warsaw-based Zimmer Biomet Holdings Inc. (NYSE: ZBH) says it has received clearance from the U.S. Food and Drug Administration for new knee replacement technology. The orthopedic device maker says the device gives surgeons more options when working with younger, active patients who are experiencing arthritis.
Its branded device, Persona OsseoTi Keel Tibia, uses anatomical data in combination with 3D printing technology to build a structure that directly mimics the architecture of human cancellous – or spongey – bone.
It can be implanted without or without bone cement that creates a tight space to hold the implant against the bone.
“The predicted growth in the prevalence of arthritis in younger, active patients has made cementless total knee arthroplasty an increasingly essential option for surgeons,” said Charles Lawrie, M.D., orthopedic surgeon at Baptist Health Orthopedic Care, and a member of the Persona OsseoTi development team.
Lawrie says the system will give surgeons the ability to decided during the procedure whether bone cement is needed or not on this implant, based on bone quality and the unique needs of their patient.